Literature DB >> 12519297

Distribution of Toll-like receptor 1 and Toll-like receptor 2 in human lymphoid tissue.

Maria-Teresa Ochoa1, Annaliza J Legaspi, Zena Hatziris, Paul J Godowski, Robert L Modlin, Peter A Sieling.   

Abstract

To determine how distinct receptors of the immune system can contribute to innate immunity, we investigated the pattern of Toll-like receptor 1 (TLR1) and TLR2 expression in human lymphoid tissue. We found that TLR1 and TLR2 were co-expressed on cells of the innate immune system, including macrophages and dendritic cells. In addition, TLR1 and TLR2 were expressed in mucosa-associated lymphoid tissue on tonsillar crypt epithelium. Of the lymphoid tissue examined, spleen expressed the highest levels of TLR2. Although TLR1- and TLR2-positive cells were in close proximity to T lymphocytes in vivo, lymphocytes themselves were devoid of TLR1 and TLR2 expression. The co-expression of TLR1 and TLR2 on myeloid cells in lymphoid tissue provides the host with the ability to respond to a variety of microbial ligands at sites conducive to the generation of an immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519297      PMCID: PMC1782859          DOI: 10.1046/j.1365-2567.2003.01563.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules.

Authors:  T I Prigozy; P A Sieling; D Clemens; P L Stewart; S M Behar; S A Porcelli; M B Brenner; R L Modlin; M Kronenberg
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

2.  The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults.

Authors:  B Lemaitre; E Nicolas; L Michaut; J M Reichhart; J A Hoffmann
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

3.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells.

Authors:  M Cella; A Engering; V Pinet; J Pieters; A Lanzavecchia
Journal:  Nature       Date:  1997-08-21       Impact factor: 49.962

4.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

Authors:  R Medzhitov; P Preston-Hurlburt; C A Janeway
Journal:  Nature       Date:  1997-07-24       Impact factor: 49.962

5.  Oligoclonal expansion and CD1 recognition by human intestinal intraepithelial lymphocytes.

Authors:  S P Balk; E C Ebert; R L Blumenthal; F V McDermott; K W Wucherpfennig; S B Landau; R S Blumberg
Journal:  Science       Date:  1991-09-20       Impact factor: 47.728

6.  Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA.

Authors:  K F Tai; Y Ma; J J Weis
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages.

Authors:  L S Schlesinger; S R Hull; T M Kaufman
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

8.  Synergistic stimulation of human B lymphocytes by anti-CD40 monoclonal antibodies and synthetic lipopeptide analogues from Escherichia coli lipoprotein.

Authors:  M Edinger; W G Bessler; B Kleine
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

9.  Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium.

Authors:  U O'Doherty; R M Steinman; M Peng; P U Cameron; S Gezelter; I Kopeloff; W J Swiggard; M Pope; N Bhardwaj
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

10.  A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.

Authors:  S M Behar; S A Porcelli; E M Beckman; M B Brenner
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  6 in total

1.  The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues.

Authors:  Faiza Rharbaoui; Astrid Westendorf; Claudia Link; Sandra Felk; Jan Buer; Matthias Gunzer; Carlos A Guzmán
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

2.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

3.  Suppression of Th1 Priming by TLR2 Agonists during Cutaneous Immunization Is Mediated by Recruited CCR2+ Monocytes.

Authors:  Christopher T Johndrow; Michael F Goldberg; Alison J Johnson; Tony W Ng; Shajo Kunnath-Velayudhan; Gregoire Lauvau; Daniel H Kaplan; Graeme H Gossel; Ulrich D Kadolsky; Andrew J Yates; John Chan; William R Jacobs; Steven A Porcelli
Journal:  J Immunol       Date:  2018-11-19       Impact factor: 5.422

Review 4.  The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.

Authors:  Janne Tegder Martinsen; Jesper Damsgaard Gunst; Jesper Falkesgaard Højen; Martin Tolstrup; Ole Schmeltz Søgaard
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

5.  Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand.

Authors:  Nadeeka H De Silva; Takashi Akazawa; Viskam Wijewardana; Norimitsu Inoue; Maremichi Oyamada; Atsuko Ohta; Yuki Tachibana; Daluthgamage Patsy H Wijesekera; Mitsuru Kuwamura; Yasuko Nishizawa; Kazuyuki Itoh; Takeshi Izawa; Shingo Hatoya; Tetsuya Hasegawa; Jyoji Yamate; Toshio Inaba; Kikuya Sugiura
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

Review 6.  [Role of toll-like receptors in respiratory diseases].

Authors:  Astrid Crespo-Lessmann; Cándido Juárez-Rubio; Vicente Plaza-Moral
Journal:  Arch Bronconeumol       Date:  2009-09-17       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.